{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-036342","form_type":"8-K","ticker":"ECOR","cik":"0001560258","company_name":"electroCore, Inc.","filed_at":"2026-08-06T20:11:27+00:00","discovered_at":"2026-08-06T20:13:00.710960+00:00","generated_at":"2026-08-06T20:15:38.975126+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"electroCore Q2 2026 revenue $9.5M (+28% YoY); net loss narrows to $3.1M; raises FY 2026 guidance to >30% growth","bullets":["Q2 net sales $9.5M, up 28% YoY from $7.4M; GAAP net loss $3.1M ($0.33/share) vs $3.7M ($0.44) prior year.","Adjusted EBITDA net loss improved 26% to $1.8M from $2.4M.","Quell product line sales $1.3M, up ~700% YoY; Truvaga revenue $1.3M, up 27% YoY.","VA channel: Rx gammaCore revenue up 11% YoY; ~16,400 VA patients (2.7% penetration of addressable headache market).","Company raises FY 2026 revenue guidance to >30% year-over-year growth; targets positive Adjusted EBITDA in Q3 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-036342","json":"https://secwatch.observer/filing/0001493152-26-036342.json","markdown":"https://secwatch.observer/filing/0001493152-26-036342.md","text":"https://secwatch.observer/filing/0001493152-26-036342.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1560258/000149315226036342/0001493152-26-036342-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1560258/000149315226036342/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:15:38.975126+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}